Morgan Stanley Upgrades Charles River Laboratories to Overweight with $220 Target
CRL•Morgan Stanley upgraded Charles River Laboratories to Overweight with a $220 price target, implying roughly 14 times projected 2026 EBITDA. The broker cited improving biotech funding, preclinical demand recovery and recent portfolio restructurings as drivers for expected double-digit earnings growth through 2028.
1. Upgrade Details and Valuation Implications
Morgan Stanley raised Charles River Laboratories to an Overweight rating and set a $220 price target, reflecting an implied multiple of approximately 14 times its estimated 2026 EBITDA. This adjustment underscores the brokerage’s view that CRL’s current valuation underestimates its growth potential.
2. Improved Biotech Funding and Preclinical Demand
The brokerage noted that rising biotech investment is reviving demand for preclinical research services, particularly in safety assessment and discovery testing. This trend is expected to accelerate CRL’s core revenue streams as biopharma companies increase outsourcing of early-stage work.
3. Strategic Portfolio Restructuring
Recent acquisitions and divestitures have streamlined Charles River’s focus on regulated safety assessment, research models and biologics testing. These moves aim to sharpen operational efficiency and concentrate resources on high-margin, high-growth segments.
4. Growth Forecast Through 2028
Morgan Stanley forecasts double-digit earnings growth at CRL through 2028, driven by rising outsourcing penetration, geopolitical shifts favoring external research providers and the company’s scale advantage in preclinical services. This outlook positions Charles River to benefit from both cyclical and structural industry tailwinds.
